Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK.

Juan Marcos GonzalezArijit GanguliAlicia K MorgansBertrand F TombalSebastien J HotteHiroyoshi SuzukiHemant BhadauriaMok OhCharles D ScalesMatthew J WallaceJui-Chen YangDaniel J George

Published in: The patient (2023)

Patients with mHSPC believe the use of ADT alone is insufficient when more effective treatments are available. Efficacy is the most significant driver of patient choices. Treatment-related convenience factors can be as important as safety concerns for patients.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
radical prostatectomy
decision making
case report
patient reported outcomes
combination therapy